11β-hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes

被引：111

作者：

Stulnig, TM

Waldhäusl, W

机构：

[1] Univ Vienna, Dept Internal Med 3, Div Endocrinol & Metab, A-1090 Vienna, Austria

[2] Austrian Acad Sci, Ctr Mol Med, A-1010 Vienna, Austria

来源：

DIABETOLOGIA | 2004年 / 47卷 / 01期

关键词：

hydroxysteroid dehydrogenase; hydrocortisone; glucocorticoids; visceral obesity; diabetes mellitus; insulin resistance; adipose tissue; intra-abdominal fat; pituitary-adrenal system; Cushing's syndrome;

D O I：

10.1007/s00125-003-1284-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Obesity and Type 2 diabetes mellitus are associated with abnormal regulation of glucocorticoid metabolism that are highlighted by clinical similarities between the sequelae of insulin resistance and Cushing's syndrome, as well as glucocorticoids' functional antagonism to insulin. 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) activates functionally inert glucocorticoid precursors (cortisone) to active glucocorticoids (cortisol) within insulin target tissues, such as adipose tissue, thereby regulating local glucocorticoid action. Recent data, mainly from rodents, provide considerable evidence for a causal role of 11beta-HSD1 for the development of visceral obesity and Type 2 diabetes though data in humans are not unequivocal. This review summarizes current evidence on a possible role of 11beta-HSD1 for development of the metabolic syndrome, raising the possibility of novel therapeutic options for the treatment of Type 2 diabetes by inhibition or down-regulation of 11beta-HSD1 activity.

引用

页码：1 / 11

页数：11

共 87 条

[1] Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice [J].